UY37015A - Inhibidores de la tirosina quinasa de bruton y métodos de su uso - Google Patents

Inhibidores de la tirosina quinasa de bruton y métodos de su uso

Info

Publication number
UY37015A
UY37015A UY0001037015A UY37015A UY37015A UY 37015 A UY37015 A UY 37015A UY 0001037015 A UY0001037015 A UY 0001037015A UY 37015 A UY37015 A UY 37015A UY 37015 A UY37015 A UY 37015A
Authority
UY
Uruguay
Prior art keywords
methods
inhibitors
tyrosine kinase
bruton tyrosine
bruton
Prior art date
Application number
UY0001037015A
Other languages
English (en)
Spanish (es)
Inventor
Nidhi Arora
M Bacani Genesis
Kent Barbay Joseph
D Bembenek Scott
Min Cai
Pooley Deckhut Charlotte
Brahmananda Ghosh
Gang Li
S Tichenor Mark
D Venable Jennifer
Jianmei Wei
J M Wiener John
Yao Wu
Yaoping Zhu
Feihuang Zhang
Kun Xiao
Wei Chen
P Edwards James
D Kreutter Kevin
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UY37015A publication Critical patent/UY37015A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UY0001037015A 2015-12-10 2016-12-09 Inhibidores de la tirosina quinasa de bruton y métodos de su uso UY37015A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562265836P 2015-12-10 2015-12-10

Publications (1)

Publication Number Publication Date
UY37015A true UY37015A (es) 2017-06-30

Family

ID=57681784

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037015A UY37015A (es) 2015-12-10 2016-12-09 Inhibidores de la tirosina quinasa de bruton y métodos de su uso

Country Status (30)

Country Link
US (5) US10717745B2 (https=)
EP (2) EP3386991B1 (https=)
JP (2) JP6835846B2 (https=)
KR (1) KR102103395B1 (https=)
CN (2) CN108884106A (https=)
AR (1) AR107042A1 (https=)
AU (1) AU2016366541B2 (https=)
BR (1) BR112018011526B1 (https=)
CA (1) CA3007990C (https=)
CY (1) CY1123263T1 (https=)
DK (1) DK3386991T3 (https=)
EA (1) EA035168B1 (https=)
ES (1) ES2805835T3 (https=)
HR (1) HRP20201193T1 (https=)
HU (1) HUE049502T2 (https=)
IL (1) IL259863B (https=)
JO (1) JO3794B1 (https=)
LT (1) LT3386991T (https=)
MA (2) MA53110A (https=)
MD (1) MD3386991T2 (https=)
ME (1) ME03803B (https=)
MX (1) MX387590B (https=)
PL (1) PL3386991T3 (https=)
PT (1) PT3386991T (https=)
RS (1) RS60604B1 (https=)
SI (1) SI3386991T1 (https=)
SM (1) SMT202000404T1 (https=)
TW (1) TWI729047B (https=)
UY (1) UY37015A (https=)
WO (1) WO2017100662A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為malt1抑制劑之吡唑衍生物
US20200079790A1 (en) * 2017-03-15 2020-03-12 Janssen Sciences Ireland Unlimited Company Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN108164397B (zh) * 2018-01-18 2020-11-13 暨南大学 一类邻苯二酚衍生物及其制备方法
US20190375749A1 (en) 2018-06-11 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
ES2949871T3 (es) 2019-04-11 2023-10-03 Janssen Pharmaceutica Nv Anillos de piridina que contienen derivados como inhibidores de MALT1
US20230094146A1 (en) * 2020-01-07 2023-03-30 Medshine Discovery Inc. Deuterated thienopyridine compound
EP4301365A1 (en) 2021-03-03 2024-01-10 Janssen Pharmaceutica NV Combination therapy using a malt1 inhibitor and a btk inhibitor
AU2022284369A1 (en) 2021-06-04 2024-01-25 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
JP2024526241A (ja) 2021-06-30 2024-07-17 ヤンセン ファーマシューティカ エヌ.ベー. ブルトン型チロシンキナーゼの阻害剤及びその使用方法
KR20240046170A (ko) 2021-08-09 2024-04-08 얀센 파마슈티카 엔브이 B-세포 악성종양의 치료에 사용하기 위한 조성물
AU2023221549A1 (en) * 2022-02-18 2024-10-03 Janssen Pharmaceutica Nv Synthesis of bruton's tyrosine kinase inhibitors
WO2025262118A1 (en) 2024-06-20 2025-12-26 Janssen Pharmaceutica Nv Combination therapy using a malt1 inhibitor and a btk inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
JP2008513463A (ja) 2004-09-15 2008-05-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チアゾロピリジンキナーゼ阻害剤
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
AU2006278627B2 (en) 2005-08-08 2011-08-18 Janssen Pharmaceutica, N.V. Thiazolopyrimidine kinase inhibitors
US7427625B2 (en) * 2006-02-08 2008-09-23 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
WO2010056875A1 (en) 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
EP2471789B9 (en) * 2009-08-26 2015-03-25 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2011133609A2 (en) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
US20140249105A1 (en) 2011-07-25 2014-09-04 Diverchim Novel ceramide analogues, processes for preparing same and uses thereof
EA201591685A1 (ru) 2013-03-15 2016-01-29 Янссен Фармацевтика Нв Способы и промежуточные соединения для получения лекарственного препарата
EP3080103B9 (en) * 2013-12-11 2018-09-19 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
MD3386991T2 (ro) 2020-11-30
CN108884106A (zh) 2018-11-23
IL259863A (en) 2018-07-31
AR107042A1 (es) 2018-03-14
AU2016366541A1 (en) 2018-05-31
US11319329B2 (en) 2022-05-03
MA43409B1 (fr) 2020-10-28
AU2016366541B2 (en) 2021-05-13
US20230097422A1 (en) 2023-03-30
US20170283430A1 (en) 2017-10-05
JP6835846B2 (ja) 2021-02-24
KR20180093974A (ko) 2018-08-22
ME03803B (me) 2021-04-20
BR112018011526B1 (pt) 2024-02-27
RS60604B1 (sr) 2020-08-31
EA201891378A1 (ru) 2018-12-28
EP3719022A1 (en) 2020-10-07
US20190276471A1 (en) 2019-09-12
EP3386991B1 (en) 2020-06-03
PT3386991T (pt) 2020-08-18
US12065446B2 (en) 2024-08-20
BR112018011526A2 (pt) 2018-11-21
JP2018536686A (ja) 2018-12-13
ES2805835T3 (es) 2021-02-15
TWI729047B (zh) 2021-06-01
HUE049502T2 (hu) 2020-09-28
JP2021073286A (ja) 2021-05-13
NZ742484A (en) 2021-09-24
US20210101910A1 (en) 2021-04-08
US10717745B2 (en) 2020-07-21
LT3386991T (lt) 2020-08-25
CN113121562B (zh) 2022-09-13
SMT202000404T1 (it) 2020-09-10
MX387590B (es) 2025-03-18
JP7072690B2 (ja) 2022-05-20
HRP20201193T1 (hr) 2020-11-13
CA3007990C (en) 2024-01-02
EP3386991A1 (en) 2018-10-17
KR102103395B1 (ko) 2020-04-23
JO3794B1 (ar) 2021-01-31
WO2017100662A1 (en) 2017-06-15
CA3007990A1 (en) 2017-06-15
IL259863B (en) 2020-06-30
CN113121562A (zh) 2021-07-16
CY1123263T1 (el) 2021-12-31
PL3386991T3 (pl) 2021-03-08
US20240383914A1 (en) 2024-11-21
TW201734021A (zh) 2017-10-01
DK3386991T3 (da) 2020-07-13
MA53110A (fr) 2021-05-12
EA035168B1 (ru) 2020-05-08
MX2018007075A (es) 2018-11-09
US10934310B2 (en) 2021-03-02
SI3386991T1 (sl) 2020-08-31

Similar Documents

Publication Publication Date Title
UY37015A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
ECSP19089214A (es) Inhibidores de quinasa y usos de los mismos
MX385082B (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
CR20150524A (es) Compuestos de heteroarilo y sus usos
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
ECSP15043696A (es) Compuestos de heteroarilo y sus usos
MX375102B (es) Compuestos de ciclopropilamina como inhibidores de histona demetilasa
EA201692219A1 (ru) Способы получения противовирусных соединений
MX387487B (es) Compuestos polifluorados que actúan como inhibidores de la tirosina cinasa de bruton.
EA201690098A1 (ru) Конденсированные трициклические соединения мочевины в качестве ингибиторов киназы raf и/или димера киназы raf
EA201492056A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
UY35500A (es) Indazoles sustituidos con heteroarilo
MX2015009719A (es) Inhibidores benzoquinolona de vmat2.
MX2017014459A (es) Compuestos de tioeter como inhibidores de la nitrificacion.
MX2017007377A (es) Compuestos organicos.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
MX374555B (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
UY35876A (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
BR112018005795A2 (pt) inibidor de quinase de egfr e método de preparação e seu uso

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20231226